Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least  days after the last dose of study drug.
Patients capable of fathering children must agree to use an effective method of contraception for the duration of the trial.
Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for  months after completion of study therapy (see Section ..).
Pregnancy or breastfeeding; patients of childbearing capability should agree to use contraception
Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least  days after the last dose of IP.
All patients of reproductive potential (heterosexually active men and women) must agree to a use of a barrier method of contraception and a second method of contraception and men must agree not to donate sperm during the study and for  weeks after receiving the last dose of study treatment
For both male and female subjects, willingness to use adequate contraception.
Women of childbearing potential must agree to use an adequate method of contraception during the study and until  months after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until  months after the last treatment
Males must agree to use an acceptable form of contraception per institutional practices
Women of childbearing potential must agree and commit to the use of a highly effective method of contraception; men must agree and commit to use a barrier method of contraception while on treatment and for  months after last dose of investigational products
Patients are not of childbearing potential or they must agree to use a physical method of contraception.
Participants must agree to use appropriate contraception.
Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least  days after the last dose of study drug.
Male patients with a female partner of childbearing potential should agree to use a barrier method of contraception, or agree to abstain from heterosexual activity for the course of the study through  days after the last dose of trial treatment
Female patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until  days after the last dose of the investigational product; male patients must agree and commit to use a barrier method of contraception while on treatment and for  months after the last dose of the investigational product
Male subjects must agree to use effective contraception or abstinence while on study and for  days after infusion of the ACTolog T-cell product.
Males must agree to abstain from sexual activity or agree to utilize a medically-approved contraception method during and for  months after the treatment period
All patients must use adequate contraception during participation in this trial and for  months following completing therapy
Women of child bearing potential must agree to use of a highly effective method of contraception from the time of informed consent until  months after the last dose of ado-trastuzumab emtansine; men must agree to use a barrier method of contraception while on treatment and for  months after the last dose of ado-trastuzumab emtansine
Male participants must be willing to use an adequate method of contraception
Female patients of childbearing potential must be willing to use  adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study, starting with visit 
Male patients must agree to use an adequate method of contraception for the duration of the study
Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study
Participants of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least  weeks after T cell infusion
Participants of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least  weeks after T cell infusion
Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study
Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study
Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for  months after completion of study therapy.
Male participants of childbearing potential must agree to use an adequate method of contraception.
. Participants must agree to use an adequate method contraception.
Male patients must agree to use effective contraception or be abstinent while on study and for  days after the infusion of IMA product
Male subjects should agree to use an adequate method of contraception during the course of the study.
The patient must be willing to comply with fertility requirements as below:\r\n* Male patients must agree to use an adequate method of contraception for the duration of the study and for  days afterwards\r\n* Female patients must be either postmenopausal, free from menses >=  yrs, surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from heterosexual activity starting with screening ( weeks prior to initiating treatment) and for  days after treatment, per POMALYST REMS program\r\n* Patients must agree not to donate blood, sperm/ova during the course of taking protocol therapy and for at least  weeks after stopping treatment
All patients of reproductive potential (heterosexually active men and women) must agree to a use of a barrier method of contraception and a second method of contraception and men must agree not to donate sperm during the study and for at least  weeks after receiving the last dose of study treatment
Patients must agree to use dual forms of contraception from the time of consent until  months after completion of the study
Female patients of childbearing potential (a female not free from menses >  years or not surgically sterilized) must be willing to use an adequate barrier method of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study; male patients who are able to father children must use an adequate barrier method of contraception
Man, who is sexually active with a woman of child-bearing potential potential must agree to use a latex or synthetic condom, even if he had a successful vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and for  weeks after last dose of lenalidomide and  months after last dose of daratumumab
commit to continued abstinence from heterosexual intercourse, or agree to use and be able to comply with the use of double-barrier contraception
Agree to use contraception per protocol
Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least  months after completion of study.
Females must be surgically or biologically sterile or postmenopausal or, if of childbearing potential, must agree to use an adequate method of contraception during the study until  days after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until  days after the last treatment
Male patients should be documented to be sterile or agree to use barrier contraception
Use of adequate contraception (as described in protocol)
Patient and his/her partner agree to use adequate contraception after providing written informed consent through  months after the last dose of PBI , as follows:
Patients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of <% per year) during the study and for  weeks after the Follow-up visit.
Women of childbearing potential must agree and commit to the use of a highly effective method of contraception as determined to be acceptable by the investigator, from the time of informed consent until  days after the last dose of the investigational product; men must agree and commit to use a barrier method of contraception while on treatment and for  months after last dose of investigational products
Females must be surgically or biologically sterile or postmenopausal or if of childbearing potential, must agree to use an adequate method of contraception during the study until  days after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until  days after the last treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
Males are eligible to enter and participate in the study if they have either had a prior vasectomy or agree to avoid sexual activity or use adequate contraception from screening through two months post the last dose of decitabine
Patients who are sexually active with a partner who could become pregnant are to use an effective form of barrier contraception, such as condoms or a partner using oral contraceptive pills; persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least  weeks after ipilimumab is stopped
Female patients (including those <  year post-menopausal) and male patients who have not undergone previous surgical sterilization must agree to use contraception
Female of childbearing potential must be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation), abstinent (at the discretion of the investigator), or agree to use adequate contraception since signing of the informed consent form until at least  months after the last study drug administration. Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >  years. - Males must agree to use adequate contraception since signing of the informed consent form until at least  months after the last study drug administration. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) at the discretion of the investigator.
Male patients agree to use an adequate method of contraception for the duration of the study
Male patients agree to use an adequate method of contraception for the duration of the study
Patients must be willing and able to comply with the FDA mandated iPLEDGE program for treatment with isotretinoin (cRA). Patients must sign specific informed consents for treatment with cRA, as mandated by iPLEDGE guidelines. Women of childbearing potential must not be pregnant, must not be breast-feeding and must practice adequate contraception during and one month after participation in the study. Male and Female patients on treatment with vorinostat must agree to use an adequate method of contraception for the duration of the study, and for  days after the last dose of study medication.
If sexually active, the patient must agree to use contraception considered adequate and appropriate by the investigator
If sexually active, the patient must agree to use contraception considered adequate and appropriate by the investigator
Sexually active patients must agree to use adequate contraception (abstinence or barrier contraceptives must be used throughout the trial and one month after end of treatment) for the duration of the study
Male patients must agree to use an adequate method of contraception.
Male patients with partners of childbearing potential must agree to use adequate contraception (barrier method or abstinence) during the study, including the follow-up time period.
Agree to use adequate contraception
Agree to use contraception
Agree to use contraception
Females must be surgically sterile, one year post menopausal or negative results for a pregnancy test performed at Screening and agree to use two methods of contraception; Males who have not had a vasectomy must agree to two methods of contraception
Male or female ?  years of age. Females of childbearing potential must agree to use an adequate and reliable method of contraception.
Agree to use adequate contraception
Patients capable of fathering children must agree to use an effective method of contraception for the duration of the trial and should continue use for  months after last dose of study drug
Male subjects must agree to use medically accepted form of contraception during the study period. Abstinence is an acceptable method of contraception.
Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least  weeks after ipilimumab is stopped
Females of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on study drug and for  months after discontinuation from study drug, and must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc), barrier method contraception (i.e. condoms), or abstinence during that time frame
Agree to contraception requirements.
Male patients are to agree to use a barrier method of contraception from study treatment initiation until at least  days after the last administration of Folotyn
Willingness to use adequate contraception for  months after completion of all therapy
Willingness to use adequate contraception for  months after completion of all therapy
Patient must be a candidate for systemic therapy with erlotinib based on clinical assessment; patients must meet the following criteria before beginning therapy (Note: these are not required for initial study enrollment and plasma genotyping):\r\n* ECOG performance status of -\r\n* Platelets > \r\n* Aspartate aminotransferase (AST) & alanine aminotransferase (ALT) <  x the upper limit of normal\r\n* Creatinine clearance >  mL/min by Cockroft-Gault\r\n* No other contraindication to erlotinib\r\n* Female participants of child-bearing age must agree to use adequate contraception (hormonal, barrier or abstinence) for the duration of the study while receiving erlotinib and undergo a pregnancy test; any evidence or suspicion of pregnancy should be reported to the treating physician immediately\r\n* Male participants must agree to use adequate contraception for the duration of the study while receiving erlotinib
Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least  days after the last dose of study drug.
